Preparation of highly activated natural killer cells for advanced lung cancer therapy.

Xie, Silun; Wu, Zhenyi; Niu, Lizhi; Chen, Jibing; Ma, Yunkun; Zhang, Mingjie

Xie, Silun; Wu, Zhenyi; Niu, Lizhi; Chen, Jibing; Ma, Yunkun; Zhang, Mingjie.

Afiliação

Xie S; Research and Development Department, HANK Bioengineering Co.,Ltd, Shenzhen, People's Republic of China.
Wu Z; Research and Development Department, HANK Bioengineering Co.,Ltd, Shenzhen, People's Republic of China.
Niu L; Department of Oncology, Fuda Cancer Hospital, Jinan University, Guangzhou, People's Republic of China.
Chen J; Department of Central Laboratory, Fuda Cancer Hospital, Jinan University, Guangzhou, People's Republic of China.
Ma Y; Research and Development Department, HANK Bioengineering Co.,Ltd, Shenzhen, People's Republic of China.
Zhang M; Research and Development Department, HANK Bioengineering Co.,Ltd, Shenzhen, People's Republic of China.

Onco Targets Ther ; 12: 5077-5086, 2019.

Article em En | MEDLINE | ID: mdl-31308687

Palavras-chave

adoptive immunotherapy; highly activated natural killer cells; immune function; lung cancer

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Onco Targets Ther Ano de publicação: 2019 Tipo de documento: Article